Chemotherapy and Targeted Therapy

Scientific Breakthroughs and Social Unrest: A Tense Week at the ADA Annual Conference

Pevita Pearce June 20, 2026

The American Diabetes Association’s (ADA) annual scientific sessions, typically a forum for the sterile exchange of clinical...

Bridging the Gap: Bionews Unveils “The Rare Journey,” an Immersive Digital Leap for the Rare Disease Community bridging-the-gap-bionews-unveils-the-rare-journey-an-immersive-digital-leap-for-the-rare-disease-community

Bridging the Gap: Bionews Unveils “The Rare Journey,” an Immersive Digital Leap for the Rare Disease Community

Nana Muazin June 20, 2026

PENSACOLA, Florida — August 19, 2024 — For millions of individuals worldwide, the diagnosis of a rare...

The FDA’s Commissioner’s National Priority Voucher: A Seismic Shift or Regulatory Turbulence? the-fdas-commissioners-national-priority-voucher-a-seismic-shift-or-regulatory-turbulence

The FDA’s Commissioner’s National Priority Voucher: A Seismic Shift or Regulatory Turbulence?

Basiran June 20, 2026

The pharmaceutical landscape is currently navigating a period of unprecedented regulatory evolution. In June 2025, the U.S....

Biopharma Industry Update: Executive Transitions, Clinical Breakthroughs, and Regulatory Shifts biopharma-industry-update-executive-transitions-clinical-breakthroughs-and-regulatory-shifts

Biopharma Industry Update: Executive Transitions, Clinical Breakthroughs, and Regulatory Shifts

Reynand Wu June 19, 2026

The landscape of the pharmaceutical and biotechnology sectors remains in constant flux, defined by high-stakes executive maneuvers,...

Biogen’s Strategic Pivot: Acquisition of RayThera Signals Aggressive Expansion into Immunology biogens-strategic-pivot-acquisition-of-raythera-signals-aggressive-expansion-into-immunology

Biogen’s Strategic Pivot: Acquisition of RayThera Signals Aggressive Expansion into Immunology

Laily UPN June 18, 2026

Biogen, long recognized as a titan in the neurology space, is formally pivoting toward a diversified future....

Biotech IPO Window Reopens: Kardigan’s $400 Million Debut Signals Renewed Investor Appetite biotech-ipo-window-reopens-kardigans-400-million-debut-signals-renewed-investor-appetite

Biotech IPO Window Reopens: Kardigan’s $400 Million Debut Signals Renewed Investor Appetite

Asro June 18, 2026

By Gwendolyn Wu | Published June 17, 2026 The biotechnology sector, which has navigated a turbulent financial...

Jazz Pharmaceuticals and AbCellera Forge Strategic Alliance to Tackle Solid Tumors with Multispecific Antibodies jazz-pharmaceuticals-and-abcellera-forge-strategic-alliance-to-tackle-solid-tumors-with-multispecific-antibodies

Jazz Pharmaceuticals and AbCellera Forge Strategic Alliance to Tackle Solid Tumors with Multispecific Antibodies

Evan Lee Salim June 17, 2026

Executive Summary In a strategic move to bolster its oncology pipeline, Jazz Pharmaceuticals has announced a high-stakes...

Clinical Uncertainty Clouds Edgewise Therapeutics’ Latest Heart Drug Data clinical-uncertainty-clouds-edgewise-therapeutics-latest-heart-drug-data

Clinical Uncertainty Clouds Edgewise Therapeutics’ Latest Heart Drug Data

Raul Delapena Setiawan June 17, 2026

By Jonathan Gardner Published June 16, 2026 The cardiovascular therapeutic landscape remains in a state of high-stakes...

The Battle Over the Prescription Counter: Tennessee’s FAIR Rx Act Faces Legal Firestorm the-battle-over-the-prescription-counter-tennessees-fair-rx-act-faces-legal-firestorm

The Battle Over the Prescription Counter: Tennessee’s FAIR Rx Act Faces Legal Firestorm

Nila Kartika Wati June 16, 2026

The landscape of the American pharmaceutical supply chain is undergoing a seismic shift as state governments attempt...

The Decade-Long Evolution: How Functional NAMs Are Revolutionizing Cardiac Safety Assessment the-decade-long-evolution-how-functional-nams-are-revolutionizing-cardiac-safety-assessment

The Decade-Long Evolution: How Functional NAMs Are Revolutionizing Cardiac Safety Assessment

Dwi Wanna June 16, 2026

In the high-stakes world of pharmaceutical development, the shift away from traditional animal-based testing has often been...

Chemotherapy and Targeted Therapy

Bridging the Gap: Bionews Unveils “The Rare Journey,” an Immersive Digital Leap for the Rare Disease Community

The FDA’s Commissioner’s National Priority Voucher: A Seismic Shift or Regulatory Turbulence?

Biopharma Industry Update: Executive Transitions, Clinical Breakthroughs, and Regulatory Shifts

Biogen’s Strategic Pivot: Acquisition of RayThera Signals Aggressive Expansion into Immunology

Biotech IPO Window Reopens: Kardigan’s $400 Million Debut Signals Renewed Investor Appetite

Jazz Pharmaceuticals and AbCellera Forge Strategic Alliance to Tackle Solid Tumors with Multispecific Antibodies

Clinical Uncertainty Clouds Edgewise Therapeutics’ Latest Heart Drug Data

The Battle Over the Prescription Counter: Tennessee’s FAIR Rx Act Faces Legal Firestorm

The Decade-Long Evolution: How Functional NAMs Are Revolutionizing Cardiac Safety Assessment

You may have missed

Ibuprofen: Beyond Pain Relief – Unveiling its Unexpected Anti-Cancer Potential

A Paradigm Shift in HIV Care: Gilead and Merck’s Once-Weekly Regimen Passes Phase 3 Milestone

Beyond Wrinkles: The Emerging Role of Botox in Revolutionizing Scar Management

The Radiology Crisis: Escalating Costs and Workforce Shortages Threaten Patient Care